Page last updated: 2024-08-18

thiophenes and Blood Clot

thiophenes has been researched along with Blood Clot in 209 studies

Research

Studies (209)

Timeframe	Studies, this research(%)	All Research%
pre-1990	35 (16.75)	18.7374
1990's	2 (0.96)	18.2507
2000's	42 (20.10)	29.6817
2010's	129 (61.72)	24.3611
2020's	1 (0.48)	2.80

Authors

Authors	Studies
Cao, X; Gu, J; Li, X; Liu, P; Miao, Y; Sun, D; Xu, Z; Zhang, J	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Badolia, R; Borst, O; Campbell, RA; Kunapuli, SP; Manne, BK; Middleton, E; Münzer, P; Rondina, MT; Walker-Allgaier, B; Weyrich, AS	1
Qian, HL; Xu, S; Zhu, LZ	1
Ge, PX; Gu, TT; Huang, BB; Ji, JZ; Jia, YM; Li, YF; Mi, QY; Tai, T; Xie, HG; Zhou, H; Zhu, T	1
Bock, F; Hartung, K; Isermann, B; Meyer, F	1
Dalmau, FG	1
Kamphuisen, PW; Lisman, T; Northup, PG; Porte, RJ	1
Eby, C	1
Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Chakrabarti, AK; Cohen, M; Gibson, CM; Goto, S; Mega, J; Mohanavelu, S; Stone, G; Verheugt, FW	1
Berkowitz, SD; Burton, P; Cook-Bruns, N; DiBattiste, PM; Haskell, L; Jalota, S; Kubitza, D; Lensing, AW; Misselwitz, F; Moore, KT; Nadel, A; Nessel, CC; Oppenheimer, L; Pan, G; Perzborn, E; Peters, G; Sarich, TC; Sun, X; Weber, J; Westermeier, T	1
Becka, M; Gouya, G; Kapiotis, S; Kubitza, D; Mueck, W; Wolzt, M	1
Baruch, L	1
Acosta, J; Benezet, J; Cubero Gómez, JM; Díaz DE LA Llera, LS; Fernández-Cisnal, A; Parejo, J; Rangel, D; Zafra, F	1
Pruthi, RK	1
Ansell, J; Shameem, R	1
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G	1
Antman, EM; Braunwald, E; Cannon, CP; Giugliano, RP; Mogabgab, O; Sabatine, MS; Sloan, S; Wiviott, SD	1
Chandler, WL	1
Nagatsuka, K; Okata, T; Takasugi, J; Toyoda, K; Yamagami, H	1
Casassus, F; Fiore, M; Horovitz, A; Leroux, L; Pons, AC	1
Baran, J; Kułakowski, P; Sikora-Frąc, M; Stec, S; Zaborska, B	1
Avram, MJ; Benzon, HT; Bonow, RO; Green, D	1
Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A	1
Hosokawa, K; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H; Tanaka, KA	1
Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA	1
Angiolillo, DJ; Capodanno, D	1
Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J	1
Meddahi, S; Samama, MM	1
Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; De Luca, G; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Ramazzotti, RN; Valenti, R	1
Bouatou, Y; Gabrielli, A; Saudan, P	1
Hagii, J; Hitomi, H; Kamada, T; Kimura, Y; Metoki, N; Okumura, K; Osanai, T; Saito, S; Shiroto, H; Tomita, H; Yasujima, M	1
Corrada, E; Ferri, M; Savonitto, S	1
Hess, T; Konturek, P	1
Fernández Guerrero, JC; Garcelán Trigo, JA; Lozano Cabezas, C; Padilla Pérez, M; Salas Bravo, D; Torres Llergo, J; Vazquez Ruiz de Castroviejo, E	1
Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y	1
Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X	1
Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Lambert, M; Morange, P; Pankert, M; Quilici, J; Verdier, V	1
Carroll, VS; Frei, J	1
Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M	1
Hantson, P; Hermans, C; Lambert, C	1
Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR	1
Chieffo, A; Colombo, A	1
Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW	1
Huynh, K	1
Blann, AD	1
Bruckner, T; Hess, A; Katus, HA; Kieser, M; Mereles, D; Pohlmeier, M; Scholz, E; Schweizer, PA; Thomas, D; Zitron, E; Zylla, MM	1
Iaroslavskaia, EI; Khor'kova, NIu; Rychkov, AIu	1
Helft, G	1
Keaney, JF	1
Guyatt, G; Spencer, FA	1
Cappato, R; Cohen, A; Hammerstingl, C; Kirsch, B; Lip, GY; Marin, F; Meng, IL; Morandi, E; van Eickels, M	1
Kereiakes, DJ; Mauri, L; Yeh, RW	1
Sipahi, I	1
Dohan, JL	1
Marrs, JC	1
Jeger, R; Kaiser, C; Pfisterer, M	1
Tomoda, H	1
Bianchi, CF; Petrucci, O	1
Abouassi, S; Abouchakra, L; Badaoui, G; Khabbaz, Z	1
Beyer-Westendorf, J	1
Abbate, R; Gensini, GF; Gori, AM; Marcucci, R	1
Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF	1
Klauss, V; Krötz, F; Sohn, HY	1
Wiviott, SD	1
Hess, C	1
Abu-Fadel, M; Norgard, NB	2
Oberpichler-Schwenk, H	1
Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC	1
Darius, H	2
Serebruany, VL	1
Arnaout, L; Bellamy, L; Rosencher, N	1
Rees, C; Spinler, SA	1
Curtiss, FR; Fairman, KA	1
Eberli, FR; Roffi, M	1
Alban, S	1
Kereiakes, DJ	1
Baker, WL; White, CM	1
Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H	1
Blázquez-Pérez, A; Gómez-Outes, A; Pozo-Hernández, C; Suárez-Gea, ML; Vargas-Castrillón, E	1
Guerra, DR; Tcheng, JE	1
Islam, AM; Patel, PM	1
Gladding, P; Webster, M; White, H	1
Bareiss, P; Kessler, L; Morel, O; Ohlmann, P	1
Weitz, JI	1
Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A	1
Freeman, MK	1
Devabhakthuni, S; Seybert, AL	1
Shakib, S; Tadros, R	1
Pakhomov, IaM	1
Panchenko, EP	1
Antman, EM; Braunwald, E; Wiviott, SD	1
Gurbel, PA; Mahla, E; Metzler, H; Tantry, US	1
Amiral, J; Depasse, F; Guinet, C; Perzborn, E; Samama, MM	1
Laizure, SC; Parker, RB	1
Braber, TL; Van Der Have-Roeffel, SM; van Werkum, JW; Verheggen, PW	1
De Rosa, G; Napodano, M; Padrini, R; Pengo, V; Plebani, M; Silvano, M; Zambon, CF	1
Penka, M	1
Stiefelhagen, P	1
Hao, M; Li, Y; Yang, W; Zhang, SW	1
Ageno, W; Romualdi, E	1
Storey, RF	1
Briongos Figuero, S; de Juan-Bagudá, J; Martí-Sánchez, D; Salido-Tahoces, L	1
Chitose, T; Hokimoto, S; Kaikita, K; Ogawa, H; Ono, T; Tsujita, K; Yamamoto, K	1
Behr, T; Behr, W; Kuch, B; von Scheidt, W	1
Ernest, CS; Li, YG; Luo, J; Macias, WL; Ni, L; Riesmeyer, JS; Rohatagi, S; Salazar, DE; Small, DS; Weerakkody, GJ; Wrishko, RE	1
Delbeck, M; Ellinghaus, P; Kast, R; Laux, V; Nickel, KF; Perzborn, E; Schäfer, S; Schermuly, RT; Strassburger, J; von Degenfeld, G	1
Flaherty, MP; Johnston, PV; Rade, JJ	1
Kazmi, RS; Lwaleed, BA	1
Buerke, M; Hauroeder, B; Kaeberich, A; Linde, T; Maegdefessel, L; Perzborn, E; Raaz, U; Reindl, I; Schlitt, A; Steinseifer, U; Vogt, A; Werdan, K	1
Brott, BC; Dobbs, JC; Hillegass, WB; Misra, VK; Papapietro, SE; Zoghbi, GJ	1
Close, SL; Erlinge, D; Jakubowski, JA; Leishman, AG; Riesmeyer, JS	1
Beddingfield, R; Held-Godgluck, BM; Peppard, SR	1
Rayoo, R; Sharma, N; van Gaal, WJ	1
Baumbach, A; Davis, A; Edmond, J; Johnson, TW; Kesavan, S; Oriolo, V; Reeves, BC; Smith, D; Strange, JW	1
Durand, M; Emmerich, J; Fischer, AM; Godier, A; Le Bonniec, B; Lecompte, T; Marchand-Leroux, C; Miclot, A; Samama, CM	1
Barakoti, M; Neupane, P; Pant, S; Ramesh, KC	1
Alves, C; Batel-Marques, F; Macedo, AF	1
Dressel, T; Konstantinides, S; Schäfer, K; Wagner, NM	1
Ageno, W; Crowther, M; Gallus, AS; Hylek, EM; Palareti, G; Wittkowsky, A	1
Abbate, A; Biondi-Zoccai, G; D'Ascenzo, F; Lotrionte, M; Modena, MG	1
Soff, GA	1
Campbell, JA; Davis, EM; Knezevich, JT; Packard, KA	1
Favaloro, EJ; Lippi, G	1
Clavé, A; Dumser, D; Fazilleau, F; Lacroix, J	1
Gibson, CM; Gopalakrishnan, L; Kohli, P; Kumar, V; Rastogi, U; Singh, P	1
Lyseng-Williamson, KA	1
Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T	1
Freynhofer, MK; Höchtl, T; Huber, K; Mahla, E; Prüller, F	1
Barn, K; Steinhubl, SR	1
Bernlochner, I; Braun, S; Kastrati, A; Koch, W; Mayer, K; Morath, T; Schömig, A; Schulz, S; Sibbing, D	1
Chan, MY; Li, Y	1
Asada, Y; Funatsu, T; Iwatsuki, Y; Kaku, S; Yamashita, A	1
Becker, RC; Chan, MY; Cyr, D; Kajikawa, M; Lin, M; Lucas, J; Moseley, A; Ortel, TL; Thompson, JW; Ueda, H	1
Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E	1
Valle Bernad, R	1
Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G	1
Hesse, C; Lindhoff-Last, E; Mani, H; Stratmann, G	1
Baeriswyl, G; Cook, S; Goy, JJ; Lehmann, S; Lehner, C; Oberhänsli, M; Puricel, S; Stauffer, JC; Togni, M	1
Fitchett, DH	1
Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A	1
Arthur, AS; Hoit, DA; Jones, GM; Twilla, JD	1
Ortel, TL	1
Gross, PL; Weitz, JI	1
Chidiac, J; Jamshedov, J; Klein, C; Mirshahi, M; Mirshahi, P; Mirshahi, S; Perzborn, E; Soria, C; Soria, J; Varin, R	1
Hashimoto, M; Jakubowski, J; Ogawa, T; Ohno, K; Sugidachi, A; Tomizawa, A	1
Hammerstingl, C; Nickenig, G; Pötzsch, B	1
Collen, A; Grimbergen, J; Hanemaaijer, R; Koolwijk, P; Lupu, F; Peters, E; Quax, PH; van Hinsbergh, VW; van Lent, N	1
Asai, F; Jakubowski, JA; Niitsu, Y; Sugidachi, A	1
Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD	1
Eikelboom, JW; Weitz, JI	1
Agnelli, G; Gallus, A; Goldhaber, SZ; Haas, S; Huisman, MV; Hull, RD; Kakkar, AK; Misselwitz, F; Schellong, S	1
Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Jakubowski, JA; Li, Y; Linden, MD; Michelson, AD; Sugidachi, A; Winters, KJ	1
Eikelboom, JW; Hirsh, J; O'Donnell, M	1
Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD	1
Asai, F; Hashimoto, M; Isobe, T; Jakubowski, JA; Niitsu, Y; Ogawa, T; Otsuguro, K; Sugidachi, A	1
Angiolillo, DJ	1
Benoist, A; De Nanteuil, G; Gaertner, R; Mennecier, P; Richard, I; Rupin, A; Verbeuren, TJ	1
Antman, EM; Braunwald, E; Downey, WE; Herrman, JP; Horvath, I; Keltai, M; McCabe, CH; Murphy, SA; Scirica, BM; Van de Werf, F; Wiviott, SD	1
Harenberg, J; Wehling, M	1
De Servi, S; Lettino, M	1
Ajani, AE; Lefkovits, J	1
Califf, RM; Fox, KA; Mahaffey, KW; Patel, MR; Piccini, JP	1
Alvarez, W	1
Glusa, E	1
Verstraete, M	2
Breddin, HK; Pauliks, V; Weichert, W	1
Kester, RC	1
Gaillard, JL; Kher, A; Lecompte, T; Samama, M	1
Gordon, JL	1
Blanchard, J; Panak, E; Roe, RL	1
Takayama, T	2
Pinon, JF	1
Kholoussy, AM; Kumashiro, R; Matsumoto, T; Pavlides, CA	1
Blanchard, J; Maffrand, JP; Panak, E; Picard-Fraire, C; Roncucci, R; Vallée, E	1
Bertelé, V; de Gaetano, G	2
Benghozi, R; Bienvenu, MP; Castaigne, A	1
Dewanjee, MK; Fuster, V; Kaye, MP; Murphy, KP; Pumphrey, CW; Vlietstra, RE	1
Kawaguchi, Y; Kobayashi, K; Koshikawa, S; Maeda, K; Naito, C; Shimizu, N	1
Kawaguchi, S; Kobayashi, K; Maeda, K; Narita, M; Ohbayashi, S; Ohta, K; Saito, A; Shinzato, T; Usuda, M	1
Curtet, JM; Guilmet, D; Renner, C	1
Bailey, DL; Bastian, JA; Briggs, SL; Chirgadze, NY; Clawson, DK; Denney, ML; Gifford-Moore, DS; Harper, RW; Johnson, LM; Klimkowski, VJ; Kohn, TJ; Lin, HS; McCowan, JR; Richett, ME; Sall, DJ; Smith, AJ; Smith, GF; Snyder, DW; Takeuchi, K; Utterback, BG; Yan, SC; Zhang, M	1
Becker, MR; Bentley, R; Bostwick, J; Brown, K; Cha, D; Cheney, DL; Choi-Sledeski, YM; Chu, V; Colussi, D; Davis, RS; Dunwiddie, CT; Ewing, WR; Green, D; Guilloteau, JP; Kasiewski, CJ; Leadley, RJ; Maignan, S; Manetta, VE; Mason, H; Mason, JS; Morgan, SR; Pauls, HW; Perrone, MH; Spada, AP	1
Bailey, DL; Bastian, JA; Buben, JA; Chirgadze, NY; Clemens-Smith, AC; Denney, ML; Fisher, MJ; Giera, DD; Gifford-Moore, DS; Harper, RW; Johnson, LM; Klimkowski, VJ; Kohn, TJ; Lin, HS; McCowan, JR; Palkowitz, AD; Richett, ME; Sall, DJ; Smith, GF; Snyder, DW; Takeuchi, K; Toth, JE; Zhang, M	1
Asai, F; Inoue, T; Koike, H; Ogawa, T; Sugidachi, A	1
Berg, DT; Calnek, DS; Ciaccia, AV; Grinnell, BW; Joyce, DE; Richardson, MA	1
Abrahamsen, CT; Barone, FC; Brooks, DP; Campbell, WG; Contino, LC; Edwards, RM; Grygielko, ET; Laping, NJ; Nelson, AH; Pullen, MA	1
Dechavanne, M; Lagarde, M	1
Altomonte, F; Armani, U; Griffanti-Bartoli, F; Piana, A; Pitton, L	1
Abiko, Y; Ashida, S; Kakihata, K; Tomikawa, M	1
Cannizzaro, S; Davì, G; Giubilato, A; Strano, A	1
Hayashida, N	1
Harker, LA	1
Asai, F; Ito, T; Matsuda, K; Oshima, T; Terada, A; Ushiyama, S; Yamazaki, M	1
Almirall, L; Bastida, E; Escolar, G; Ordinas, A	1
Di Perri, T	1
Anderton, JL; Burnet, ME; Fiskerstrand, CE; Thompson, IW; Williams, P	1
Gröntoft, KC; Gutierrez, A; Mulec, H; Olander, R	1
Hashimoto, N; Kholoussy, AM; Kumashiro, R; Matsumoto, T; Piotrowski, JJ	1
Cattaneo, M; Groves, HM; Kinlough-Rathbone, RL; Mustard, JF; Packham, MA; Somers, DA; Winocour, PD	1
Glukhov, AI; Goriunov, VS; Kirichenko, AA; Smirnova, LA	1
Hampton, JR; Harrison, MJ; Honour, AJ; Mitchell, JR; Prichard, JS	1

Reviews

70 review(s) available for thiophenes and Blood Clot

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
[From heparin to apixaban: anticoagulants cut both ways?]. Zentralblatt fur Chirurgie, 2014, Volume: 139, Issue:1 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; International Normalized Ratio; Liver Failure; Metabolic Clearance Rate; Morpholines; Perioperative Care; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis; Vitamin K	2014
[The new oral anticoagulants in special populations]. Medicina clinica, 2012, Volume: 139 Suppl 2 Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis	2012
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats. Journal of hepatology, 2013, Volume: 59, Issue:2 Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Liver Cirrhosis; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K	2013
Novel anticoagulants and laboratory testing. International journal of laboratory hematology, 2013, Volume: 35, Issue:3 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis	2013
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Annals of the New York Academy of Sciences, 2013, Volume: 1291 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2013
Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants. Postgraduate medicine, 2013, Volume: 125, Issue:2 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis	2013
Review of the American College of Chest Physicians 2012 Guidelines for Anticoagulation Therapy and Prevention of Thrombosis. Seminars in hematology, 2013, Volume: 50, Issue:3 Topics: Drug Synergism; Fibrinolytic Agents; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thrombosis; United States; Vitamin K	2013
Disadvantages of VKA and requirements for novel anticoagulants. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Vitamin K; Warfarin	2013
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. The Canadian journal of cardiology, 2013, Volume: 29, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2013
New oral anticoagulants and regional anaesthesia. British journal of anaesthesia, 2013, Volume: 111 Suppl 1 Topics: Administration, Oral; Anesthesia, Conduction; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis	2013
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome. The American journal of cardiology, 2014, Mar-01, Volume: 113, Issue:5 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine	2014
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor	2014
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban]. Journal des maladies vasculaires, 2014, Volume: 39, Issue:3 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzamides; Blood Coagulation; Embolism; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia; Thrombosis	2014
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?]. Revue medicale suisse, 2014, Feb-26, Volume: 10, Issue:419 Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2014
[Gastrointestinal bleeding under treatment with new oral anticoagulants]. MMW Fortschritte der Medizin, 2014, Feb-06, Volume: 156, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Embolism; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin	2014
Oral anticoagulants: the move beyond warfarin. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 2014, Volume: 46, Issue:5 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin	2014
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory. British journal of biomedical science, 2014, Volume: 71, Issue:4 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis; Treatment Outcome; Vitamin K	2014
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. Journal of interventional cardiology, 2008, Volume: 21, Issue:4 Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine	2008
Antiplatelet drugs in cardiological practice: established strategies and new developments. Vascular health and risk management, 2008, Volume: 4, Issue:3 Topics: Atherosclerosis; Clopidogrel; Drug-Eluting Stents; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thromboxane; Signal Transduction; Thiophenes; Thrombosis; Ticlopidine	2008
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel? Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2008
Future prospects in anti-platelet therapy: a review of potential P2Y12 and thrombin receptor antagonists. Recent patents on cardiovascular drug discovery, 2008, Volume: 3, Issue:3 Topics: Adenosine Monophosphate; Animals; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Thrombosis	2008
[Rivaroxaban. The first factor Xa inhibitor]. Medizinische Monatsschrift fur Pharmazeuten, 2008, Volume: 31, Issue:11 Topics: Animals; Factor Xa Inhibitors; Heart Diseases; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis	2008
Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery? Archives of cardiovascular diseases, 2009, Volume: 102, Issue:4 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Prothrombin; Pyridines; Risk Assessment; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K	2009
Review of prasugrel for the secondary prevention of atherothrombosis. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Thrombosis; Ticlopidine	2009
Diabetes and acute coronary syndromes. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine	2009
[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist]. Pharmazie in unserer Zeit, 2009, Volume: 38, Issue:4 Topics: Animals; Biotransformation; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine	2009
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial. Reviews in cardiovascular medicine, 2009,Spring, Volume: 10, Issue:2 Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome	2009
Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombosis	2009
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vascular health and risk management, 2009, Volume: 5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2009
Prasugrel: Clinical development and therapeutic application. Advances in therapy, 2009, Volume: 26, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Thrombosis; Ticlopidine	2009
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy. Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine	2010
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis, 2010, Volume: 212, Issue:2 Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Glycoproteins; Humans; Models, Biological; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thromboplastin; Thrombosis; Ticlopidine	2010
Potential of new anticoagulants in patients with cancer. Thrombosis research, 2010, Volume: 125 Suppl 2 Topics: Anticoagulants; Benzimidazoles; Biotin; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombosis	2010
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. Hospital practice (1995), 2010, Volume: 38, Issue:2 Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
Thienopyridine antiplatelet agents: focus on prasugrel. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2010, Volume: 25, Issue:4 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Selection; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Treatment Outcome	2010
Clot prevention--common questions about medications. Australian family physician, 2010, Volume: 39, Issue:7 Topics: Anticoagulants; Aspirin; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; International Normalized Ratio; Morpholines; Pharmacogenetics; Pyridines; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism	2010
Prasugrel. Circulation, 2010, Jul-27, Volume: 122, Issue:4 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. The Annals of thoracic surgery, 2010, Volume: 90, Issue:3 Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticlopidine	2010
A comparison of the metabolism of clopidogrel and prasugrel. Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Thiophenes; Thrombosis; Ticlopidine	2010
[Rivaroxaban and factor Xa inhibitors in clinical practice]. Vnitrni lekarstvi, 2010, Volume: 56, Issue:9 Topics: Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis	2010
[New study findings in cardiology. The best is the enemy of the good]. Medizinische Monatsschrift fur Pharmazeuten, 2010, Volume: 33, Issue:11 Topics: Angioplasty, Balloon, Coronary; Angiotensin II Type 2 Receptor Blockers; Anticoagulants; Atrial Fibrillation; Cardiology; Coronary Disease; Drug-Eluting Stents; Heart Diseases; Humans; Morpholines; Myocardial Infarction; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K	2010
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:4 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drugs, Investigational; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Venous Thromboembolism	2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2011
Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors. Journal of cardiology, 2011, Volume: 58, Issue:1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis	2011
New anticoagulants: how to deal with treatment failure and bleeding complications. British journal of clinical pharmacology, 2011, Volume: 72, Issue:4 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Treatment Failure	2011
Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview. Vascular health and risk management, 2011, Volume: 7 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombosis; Time Factors; Treatment Outcome	2011
TRITON and beyond: new insights into the profile of prasugrel. Cardiovascular therapeutics, 2012, Volume: 30, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Time Factors; Treatment Outcome	2012
Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis. Journal of cardiovascular pharmacology and therapeutics, 2012, Volume: 17, Issue:3 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis	2012
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, Volume: 141, Issue:2 Suppl Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Societies, Medical; Thiophenes; Thrombosis; United States; Vitamin K	2012
A new generation of oral direct anticoagulants. Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:3 Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2012
Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome. Pharmacotherapy, 2012, Volume: 32, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Coronary Artery Disease; Hemorrhage; Humans; Imines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticagrelor	2012
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:7 Topics: Acute Coronary Syndrome; Administration, Oral; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Drug Interactions; Factor Xa; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Myocardial Infarction; Pulmonary Embolism; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thrombosis	2012
[Platelet function: new drugs, new assays : possible impacts on operative medicine?]. Der Anaesthesist, 2012, Volume: 61, Issue:6 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Postoperative Complications; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Predictive Value of Tests; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
A brief review of the past and future of platelet P2Y12 antagonist. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
Potential role of rivaroxaban in patients with acute coronary syndrome. Drug design, development and therapy, 2012, Volume: 6 Topics: Acute Coronary Syndrome; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Intracranial Hemorrhages; Morpholines; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Warfarin	2012
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:3 Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; PubMed; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2013
Perioperative management of patients on chronic antithrombotic therapy. Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Middle Aged; Morpholines; Perioperative Care; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Vitamin K	2012
New oral anticoagulants: which one should my patient use? Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hematology; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Warfarin	2012
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:2 Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic; Clopidogrel; Collagen; Drug Evaluation, Preclinical; Drug Synergism; Fibrinolytic Agents; Hemostasis; Humans; Male; Membrane Proteins; Molecular Structure; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombin; Thrombosis; Ticlopidine	2005
Beyond unfractionated heparin and warfarin: current and future advances. Circulation, 2007, Jul-31, Volume: 116, Issue:5 Topics: Angina, Unstable; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Brain Ischemia; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Forecasting; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Morpholines; Myocardial Infarction; Peptide Fragments; Polysaccharides; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Thrombosis; Warfarin	2007
ADP receptor antagonism: what's in the pipeline? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2007
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Seminars in thrombosis and hemostasis, 2008, Volume: 34, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Glycine; Humans; Infusions, Parenteral; Morpholines; Oligosaccharides; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Venous Thromboembolism	2008
Rivaroxaban, an oral direct factor Xa inhibitor. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Animals; Anticoagulants; Atrial Fibrillation; Binding Sites; Clinical Trials as Topic; Comorbidity; Drug Evaluation, Preclinical; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Rats; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin	2008
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries. Agents and actions. Supplements, 1984, Volume: 15 Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Humans; Intermittent Claudication; Leg; Platelet Aggregation; Platelet Factor 4; Suloctidil; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine	1984
[Pharmacology of anti-platelet agents]. Journal des maladies vasculaires, 1983, Volume: 8, Issue:1 Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Cyclic AMP; Cyclooxygenase Inhibitors; Dipyridamole; Epoprostenol; Female; Fibrinolytic Agents; Humans; In Vitro Techniques; Intestinal Absorption; Kinetics; Male; Papio; Platelet Aggregation; Prostaglandin Antagonists; Rabbits; Sulfinpyrazone; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine	1983
Overview: pharmacology of ticlopidine. Agents and actions. Supplements, 1984, Volume: 15 Topics: Animals; Anticoagulants; Bleeding Time; Blood Vessels; Humans; Kinetics; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine	1984
[Platelet function inhibitors in peripheral arteriopathies]. Recenti progressi in medicina, 1986, Volume: 77, Issue:4 Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases	1986
[Thrombosis in various diseases: myocardial infarct]. Nihon rinsho. Japanese journal of clinical medicine, 1986, Volume: 44, Issue:5 Topics: Angioplasty, Balloon; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine	1986
Antiplatelet drugs in the management of patients with thrombotic disorders. Seminars in thrombosis and hemostasis, 1986, Volume: 12, Issue:2 Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets; Catheterization; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Glomerulonephritis; Humans; Sulfinpyrazone; Suloctidil; Thiophenes; Thrombophlebitis; Thrombosis; Ticlopidine; Vascular Diseases; Vascular Surgical Procedures	1986

Trials

25 trial(s) available for thiophenes and Blood Clot

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. Journal of the American College of Cardiology, 2013, Jul-23, Volume: 62, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stents; Thiophenes; Thrombosis; Treatment Outcome	2013
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thrombosis research, 2013, Volume: 132, Issue:2 Topics: Adolescent; Adult; Animals; Anticoagulants; Aspirin; Cross-Over Studies; Female; Humans; In Vitro Techniques; Male; Middle Aged; Morpholines; Platelet Aggregation; Rivaroxaban; Swine; Thiophenes; Thrombosis; Venous Thromboembolism; Young Adult	2013
Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:6 Topics: Acute Coronary Syndrome; Aged; Circadian Rhythm; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome	2013
Switching from clopidogrel to prasugrel in patients having coronary stent implantation. Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:3 Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Sex Factors; Stents; Thiophenes; Thrombosis; Ticlopidine	2014
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:11 Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult	2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23 Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Time Factors	2014
Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry prov American heart journal, 2015, Volume: 169, Issue:4 Topics: Administration, Oral; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography, Transesophageal; Electric Countershock; Factor Xa Inhibitors; Female; Heart Diseases; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2015
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of clinical pharmacology, 2012, Volume: 52, Issue:6 Topics: Acute Coronary Syndrome; Age Factors; Aged; Biotransformation; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Hemorrhage; Humans; Incidence; Male; Models, Biological; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Severity of Illness Index; Thiophenes; Thrombosis	2012
Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients. Orthopaedics & traumatology, surgery & research : OTSR, 2012, Volume: 98, Issue:5 Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Bone Cements; Case-Control Studies; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Morpholines; Postoperative Hemorrhage; Prospective Studies; Prostheses and Implants; Rivaroxaban; Single-Blind Method; Thiophenes; Thrombosis; Tranexamic Acid; Treatment Outcome	2012
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thrombosis and haemostasis, 2012, Volume: 108, Issue:6 Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Proteins; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Proteomics; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin	2012
A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial. Archives of cardiovascular diseases, 2012, Volume: 105, Issue:11 Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Drugs, Generic; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Stents; Therapeutic Equivalency; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2012
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar American heart journal, 2006, Volume: 152, Issue:4 Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Syndrome; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine; Treatment Outcome	2006
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation, 2007, Jul-10, Volume: 116, Issue:2 Topics: Administration, Oral; Adult; Anticoagulants; Factor Xa Inhibitors; Heparin; Humans; Morpholines; Patient Selection; Pulmonary Embolism; Rivaroxaban; Safety; Thiophenes; Thrombosis	2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine	2007
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi Lancet (London, England), 2008, Apr-19, Volume: 371, Issue:9621 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2008
[The TRITON-TIMI 38 trial]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2008
Approaching an age of reason with antiplatelet therapy. Lancet (London, England), 2008, Apr-19, Volume: 371, Issue:9621 Topics: Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Thrombosis; Ticlopidine	2008
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries. Agents and actions. Supplements, 1984, Volume: 15 Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Humans; Intermittent Claudication; Leg; Platelet Aggregation; Platelet Factor 4; Suloctidil; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine	1984
Evaluation of the antithrombotic efficacy of ticlopidine in man. Agents and actions. Supplements, 1984, Volume: 15 Topics: Anticoagulants; Clinical Trials as Topic; Extracorporeal Circulation; Female; Fibrinolytic Agents; Humans; Leukocyte Count; Male; Premedication; Renal Dialysis; Thiophenes; Thrombocytopenia; Thrombosis; Ticlopidine	1984
Registry of prospective clinical trials--fifth report. Thrombosis and haemostasis, 1982, Dec-27, Volume: 48, Issue:3 Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Blind Method; Heart Valve Prosthesis; Heparin; Humans; Intermittent Claudication; Myocardial Infarction; Prospective Studies; Registries; Thiophenes; Thromboembolism; Thrombophlebitis; Thrombosis; Ticlopidine	1982
[Ticlopidine in heart surgery with cardiopulmonary by-pass (author's transl)]. La Nouvelle presse medicale, 1980, Nov-15, Volume: 9, Issue:43 Topics: Adolescent; Adult; Aged; Blood Coagulation; Cardiac Surgical Procedures; Extracorporeal Circulation; Humans; Middle Aged; Platelet Aggregation; Postoperative Complications; Pyridines; Thiophenes; Thrombocytopenia; Thrombosis; Ticlopidine	1980
[Platelet function inhibitors in peripheral arteriopathies]. Recenti progressi in medicina, 1986, Volume: 77, Issue:4 Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases	1986
Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial organs, 1985, Volume: 9, Issue:1 Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind Method; Graft Occlusion, Vascular; Humans; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine	1985
Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian journal of urology and nephrology, 1985, Volume: 19, Issue:1 Topics: Adult; Aged; Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Postoperative Complications; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine	1985

Other Studies

117 other study(ies) available for thiophenes and Blood Clot

Article	Year
A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y Cardiovascular drugs and therapy, 2020, Volume: 34, Issue:1 Topics: Animals; Blood Coagulation; Blood Platelets; Carrageenan; Clopidogrel; Cyclic AMP; Disease Models, Animal; Fibrinolytic Agents; Hemorrhage; Male; Mice; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats, Wistar; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis	2020
PDK1 governs thromboxane generation and thrombosis in platelets by regulating activation of Raf1 in the MAPK pathway. Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:6 Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Blood Platelets; Disease Models, Animal; Humans; Mice, Knockout; Mitogen-Activated Protein Kinases; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-raf; Pulmonary Embolism; Pyrimidines; Signal Transduction; Thiophenes; Thrombosis; Thromboxanes	2018
Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus. World journal of gastroenterology, 2018, Jun-21, Volume: 24, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters; Chemoembolization, Therapeutic; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Quinazolines; Retrospective Studies; Survival Rate; Thiophenes; Thrombosis; Treatment Outcome	2018
Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 115 Topics: Animals; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Inactivation, Metabolic; Male; Mice, Inbred C57BL; Phenylacetates; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats, Sprague-Dawley; Thiophenes; Thrombosis	2019
A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching. Journal of interventional cardiology, 2013, Volume: 26, Issue:5 Topics: Angioplasty; Antithrombins; Clopidogrel; Cohort Studies; Drug Combinations; Female; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Piperazines; Postoperative Complications; Prasugrel Hydrochloride; Recombinant Proteins; Retrospective Studies; Thiophenes; Thrombosis; Ticlopidine	2013
Anticoagulation without monitoring. American journal of clinical pathology, 2013, Volume: 140, Issue:5 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Humans; Morpholines; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin	2013
Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Female; Humans; Male; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thrombosis; Treatment Outcome	2013
First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor. Platelets, 2014, Volume: 25, Issue:8 Topics: Adenosine; Drug Resistance; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis; Ticagrelor	2014
Lysis of thrombus located in the left atrial appendage. Is it the right time for a Xa factor inhibitor? Kardiologia polska, 2013, Volume: 71, Issue:11 Topics: Aged; Anticoagulants; Atrial Appendage; Factor Xa Inhibitors; Female; Heart Diseases; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Tomography, X-Ray Computed; Vitamin K	2013
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. Journal of the American College of Cardiology, 2014, Mar-25, Volume: 63, Issue:11 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2014
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model. PloS one, 2014, Volume: 9, Issue:1 Topics: Adenosine Triphosphate; Adult; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Blood Platelets; Dabigatran; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Female; Fibrin; Humans; Lab-On-A-Chip Devices; Male; Microscopy, Confocal; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Rivaroxaban; Thiophenes; Thrombin; Thromboplastin; Thrombosis	2014
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. The American journal of emergency medicine, 2014, Volume: 32, Issue:5 Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resistance; Electrocardiography; Heparin; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine	2014
Reduced smoke-like echo and resolved thrombus in the left atrium with rivaroxaban therapy in an acute cardioembolic stroke patient. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:6 Topics: Aged; Echocardiography, Transesophageal; Embolism; Factor Xa Inhibitors; Heart Atria; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Treatment Outcome	2014
Fatal bleedings with prasugrel as part of triple antithrombotic therapy. Revista espanola de cardiologia (English ed.), 2014, Volume: 67, Issue:3 Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Arteriovenous Malformations; Aspirin; Drug Therapy, Combination; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Warfarin	2014
Resolution of left ventricular thrombus by rivaroxaban. Future cardiology, 2014, Volume: 10, Issue:3 Topics: Aged; Dose-Response Relationship, Drug; Echocardiography; Factor Xa Inhibitors; Follow-Up Studies; Heart Diseases; Heart Ventricles; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thrombosis	2014
In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:4 Topics: Acute Disease; Age Factors; Aged; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Postoperative Complications; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Registries; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States	2014
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. Science translational medicine, 2014, Aug-06, Volume: 6, Issue:248 Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemorrhage; Humans; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency	2014
Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome. International journal of cardiology, 2014, Oct-20, Volume: 176, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Postoperative Care; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Retrospective Studies; Thiophenes; Thrombosis; Ticagrelor	2014
Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2015, Volume: 26, Issue:2 Topics: Adult; Anticoagulants; Factor Xa Inhibitors; Heparin; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis	2015
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial. BMC family practice, 2014, Oct-25, Volume: 15 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism	2014
Dual antiplatelet therapy after drug-eluting stents--how long to treat? The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23 Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2014
Antiplatelet therapy: risks and benefits of extended DAPT after stenting. Nature reviews. Cardiology, 2015, Volume: 12, Issue:1 Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis; Ticlopidine	2015
Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. The American journal of cardiology, 2015, Mar-01, Volume: 115, Issue:5 Topics: Aged; Anticoagulants; Arrhythmias, Cardiac; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Prevalence; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K	2015
[Rivaroxaban for thrombosis of the left atrium in a patient with atrial flutter]. Kardiologiia, 2014, Volume: 54, Issue:10 Topics: Atrial Flutter; Catheter Ablation; Coronary Angiography; Drug Monitoring; Echocardiography, Transesophageal; Electrophysiologic Techniques, Cardiac; Factor Xa Inhibitors; Heart Atria; Heart Failure; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2014
Prolonged dual antiplatelet therapy after drug-eluting stent reduces the risk of stent thrombosis and major cardiovascular events but increases the rate of bleeding. Evidence-based medicine, 2015, Volume: 20, Issue:3 Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine	2015
Balancing the risks and benefits of dual platelet inhibition. The New England journal of medicine, 2015, May-07, Volume: 372, Issue:19 Topics: Adenosine; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2015
ACP journal club. Dual antiplatelets for 30 mo after drug-eluting stents reduced stent thrombosis and CV and cerebrovascular events. Annals of internal medicine, 2015, Mar-17, Volume: 162, Issue:6 Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine	2015
Duration of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14 Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine	2015
Duration of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14 Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine	2015
Duration of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14 Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine	2015
Duration of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14 Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine	2015
Duration of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14 Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine	2015
Duration of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14 Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine	2015
Another off-label novel oral anticoagulant to HIT cardiac surgery patients. The Journal of thoracic and cardiovascular surgery, 2015, Volume: 150, Issue:2 Topics: Anticoagulants; Coronary Artery Bypass; Factor Xa Inhibitors; Graft Occlusion, Vascular; Heparin; Humans; Male; Morpholines; Saphenous Vein; Thiophenes; Thrombocytopenia; Thrombosis	2015
Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: A case report. The Journal of thoracic and cardiovascular surgery, 2015, Volume: 150, Issue:2 Topics: Anticoagulants; Coronary Artery Bypass; Factor Xa Inhibitors; Graft Occlusion, Vascular; Heparin; Humans; Male; Middle Aged; Morpholines; Off-Label Use; Platelet Count; Radiography; Rivaroxaban; Saphenous Vein; Thiophenes; Thrombocytopenia; Thrombosis; Treatment Outcome	2015
Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism" Thrombosis research, 2016, Volume: 148 Topics: Adult; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism	2016
Intensive antiplatelet therapy for reduction of ischaemic events. Lancet (London, England), 2008, Aug-16, Volume: 372, Issue:9638 Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis	2008
[Always more amputations in Germany?]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:42 Topics: Aged; Amputation, Surgical; Anticoagulants; Arterial Occlusive Diseases; Benzimidazoles; Dabigatran; Fibrinolytic Agents; Germany; Humans; Morpholines; Peripheral Vascular Diseases; Pyridines; Rivaroxaban; Thiophenes; Thrombosis	2008
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Thiophenes; Thrombosis; Ticlopidine	2009
[New anticoagulants]. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:16 Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis	2009
Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. The American journal of medicine, 2009, Volume: 122, Issue:5 Topics: Blood Platelets; Colorectal Neoplasms; Fibrinolysis; Humans; Incidence; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Factors; Thiophenes; Thrombosis; United States	2009
Pharmacy benefit spending poised to increase for antithrombotic drug therapy -- prasugrel versus clopidogrel. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:5 Topics: Clopidogrel; Commerce; Drug Costs; Humans; Insurance, Pharmaceutical Services; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2009
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thrombosis research, 2009, Volume: 124, Issue:5 Topics: Adenosine; Animals; CHO Cells; Clopidogrel; Cricetinae; Cricetulus; Disease Models, Animal; Dogs; Hemostasis; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine; Transfection	2009
Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient? Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:12 Topics: Humans; Morpholines; Orthopedics; Postoperative Complications; Premedication; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2009
Prasugrel, Māori, and personalised medicine in New Zealand. The New Zealand medical journal, 2010, Mar-05, Volume: 123, Issue:1310 Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Markers; Genetic Testing; Humans; Native Hawaiian or Other Pacific Islander; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Precision Medicine; Stents; Thiophenes; Thrombosis; Ticlopidine; Vascular Diseases	2010
Oral antiplatelet therapy for the management of acute coronary syndromes: defining the role of prasugrel. Critical care nurse, 2011, Volume: 31, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Treatment Outcome	2011
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial]. Kardiologiia, 2010, Volume: 50, Issue:6 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
[Anticoagulant therapy in cardiology: yesterday, today, tomorrow]. Kardiologiia, 2010, Volume: 50, Issue:7 Topics: Anticoagulants; Benzimidazoles; Carboxypeptidase B2; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Receptor, PAR-1; Rivaroxaban; Thiophenes; Thrombin; Thrombomodulin; Thrombosis; Treatment Outcome; Warfarin	2010
An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thrombosis and haemostasis, 2010, Volume: 104, Issue:5 Topics: Blood Coagulation; Clinical Trials, Phase II as Topic; Colorimetry; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Male; Morpholines; Orthopedic Procedures; Predictive Value of Tests; Rivaroxaban; Thiophenes; Thrombosis	2010
Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel. Platelets, 2011, Volume: 22, Issue:1 Topics: Aged; Angioedema; Clopidogrel; Drug Hypersensitivity; Exanthema; Fever; Humans; Male; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tachycardia; Thiophenes; Thrombosis; Ticlopidine	2011
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. Journal of thrombosis and thrombolysis, 2011, Volume: 31, Issue:2 Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents; Clopidogrel; Docetaxel; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Taxoids; Thiophenes; Thrombosis; Ticlopidine	2011
[Prasugrel--oral (Efient)]. Journal de pharmacie de Belgique, 2010, Issue:4 Topics: Acute Coronary Syndrome; Drug Interactions; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis	2010
Investigation on the binding mode of benzothiophene analogues as potent factor IXa (FIXa) inhibitors in thrombosis by CoMFA, docking and molecular dynamic studies. Journal of enzyme inhibition and medicinal chemistry, 2011, Volume: 26, Issue:6 Topics: Binding Sites; Databases, Factual; Factor IXa; Humans; Models, Molecular; Molecular Dynamics Simulation; Molecular Structure; Quantitative Structure-Activity Relationship; Thiophenes; Thrombosis	2011
[Multiple arterial thrombosis and resistance to conventional antiaggregation]. Revista espanola de cardiologia, 2011, Volume: 64, Issue:9 Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography; Female; Femoral Artery; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2011
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clinical research in cardiology : official journal of the German Cardiac Society, 2011, Volume: 100, Issue:10 Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Electrodes; Female; Germany; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome	2011
A role for coagulation factor Xa in experimental pulmonary arterial hypertension. Cardiovascular research, 2011, Oct-01, Volume: 92, Issue:1 Topics: Animals; Blood Coagulation; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Morpholines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Rivaroxaban; Thiophenes; Thrombosis; Warfarin	2011
Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel. The Journal of invasive cardiology, 2011, Volume: 23, Issue:7 Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure; Treatment Outcome	2011
Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. Journal of thrombosis and thrombolysis, 2011, Volume: 32, Issue:4 Topics: Anticoagulants; Heart Valve Prosthesis; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Models, Biological; Morpholines; Perfusion; Rivaroxaban; Thiophenes; Thrombosis	2011
Use of prasugrel in a patient with clopidogrel hypersensitivity. The Annals of pharmacotherapy, 2011, Volume: 45, Issue:10 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Hypersensitivity; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2011
A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim. Heart, lung & circulation, 2012, Volume: 21, Issue:3 Topics: Acute Disease; Aspirin; Chest Pain; Clopidogrel; Eptifibatide; Female; Humans; Middle Aged; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Risk Factors; Stents; Thiophenes; Thrombosis; Ticlopidine; Ultrasonography, Interventional	2012
Prasugrel and bivalirudin for primary angioplasty: early results on stent thrombosis and bleeding. International journal of cardiology, 2011, Dec-01, Volume: 153, Issue:2 Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cohort Studies; Drug Therapy, Combination; Female; Hemorrhage; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Piperazines; Prasugrel Hydrochloride; Recombinant Proteins; Stents; Thiophenes; Thrombosis; Time Factors	2011
Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology, 2012, Volume: 116, Issue:1 Topics: Anesthesia; Animals; Anticoagulants; Bleeding Time; Blood Coagulation Tests; Blood Pressure; Body Temperature; Dose-Response Relationship, Drug; Factor VIIa; Hemorrhage; Liver; Male; Monitoring, Physiologic; Morpholines; Prothrombin; Rabbits; Recombinant Proteins; Respiration, Artificial; Rivaroxaban; Spleen; Thiophenes; Thrombelastography; Thrombin; Thrombosis	2012
Xarelto: a new drug for new joints. Hip and knee recipients can avoid postsurgical clots without undergoing painful injections. The Johns Hopkins medical letter health after 50, 2011, Volume: 23, Issue:8 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Embolism; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Thrombosis	2011
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity. Cardiology journal, 2011, Volume: 18, Issue:6 Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Metals; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2011
Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice. Thrombosis research, 2012, Volume: 130, Issue:5 Topics: Animals; Anticoagulants; Apolipoproteins E; Blood Coagulation; Disease Models, Animal; Factor Xa Inhibitors; Fibrinolytic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Rivaroxaban; Thiophenes; Thrombosis	2012
Prasugrel during primary percutaneous coronary intervention: evidence from clinical data. Current vascular pharmacology, 2012, Volume: 10, Issue:4 Topics: Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Combined Modality Therapy; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis	2012
Coagulopathies and thrombosis: usual and unusual causes and associations, part VI. Seminars in thrombosis and hemostasis, 2012, Volume: 38, Issue:2 Topics: Acute Coronary Syndrome; Altitude; Blood Coagulation Disorders; Coffee; Factor Xa Inhibitors; Heparin; Humans; Lipoproteins; Lymphatic Diseases; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis; Troponin; Venous Thrombosis; von Willebrand Diseases	2012
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Economics, Pharmaceutical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States	2012
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. Platelets, 2012, Volume: 23, Issue:5 Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
[Prasugrel]. Hamostaseologie, 2012, Volume: 32, Issue:3 Topics: Evidence-Based Medicine; Fibrinolytic Agents; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis; Treatment Outcome	2012
High frequency of CYP2C192 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring. Platelets, 2013, Volume: 24, Issue:6* Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Heterozygote; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2013
Failure of high-dose clopidogrel in recurrent stent thrombosis. Singapore medical journal, 2012, Volume: 53, Issue:8 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure	2012
Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models. Thrombosis and haemostasis, 2012, Volume: 108, Issue:5 Topics: Administration, Oral; Animals; Anticoagulants; Azepines; Benzamides; Disease Models, Animal; Factor Xa Inhibitors; Femoral Artery; Lipids; Male; Morpholines; Plaque, Atherosclerotic; Prothrombin Time; Rabbits; Rivaroxaban; Thiophenes; Thrombosis	2012
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:12 Topics: Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Morpholines; Platelet Aggregation; Rivaroxaban; Stents; Swine; Swine, Miniature; Thiophenes; Thrombosis; Ticlopidine	2012
[Introduction]. Revista clinica espanola, 2012, Volume: 212 Suppl 1 Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin	2012
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Disease-Free Survival; Drug Costs; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Health Care Costs; Hemorrhage; Humans; Insurance, Health, Reimbursement; Kaplan-Meier Estimate; Markov Chains; Medicare; Models, Economic; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States	2013
Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thrombosis and haemostasis, 2013, Volume: 109, Issue:1 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Chromatography, High Pressure Liquid; Chromogenic Compounds; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Factor Xa; Factor Xa Inhibitors; False Positive Reactions; Humans; Morpholines; Nephelometry and Turbidimetry; Predictive Value of Tests; Reproducibility of Results; Rivaroxaban; Tablets; Tandem Mass Spectrometry; Thiophenes; Thrombophilia; Thrombosis; Time Factors; Treatment Outcome	2013
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices. Journal of neurointerventional surgery, 2013, Sep-01, Volume: 5, Issue:5 Topics: Carotid Artery, Internal, Dissection; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2013
Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban. Thrombosis research, 2013, Volume: 131, Issue:3 Topics: Anticoagulants; Blood; Blood Coagulation; Blood Platelets; Erythrocytes; Factor XIII; Fibrin; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Humans; Morpholines; Permeability; Plasma; Risk Factors; Rivaroxaban; Thiophenes; Thrombin; Thrombolytic Therapy; Thromboplastin; Thrombosis; Time Factors	2013
A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. British journal of pharmacology, 2013, Volume: 169, Issue:1 Topics: Adenosine; Animals; Blood Coagulation Tests; Dose-Response Relationship, Drug; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Risk; Thiophenes; Thrombosis; Ticagrelor	2013
Resolution of giant left atrial appendage thrombus with rivaroxaban. Thrombosis and haemostasis, 2013, Volume: 109, Issue:4 Topics: Anticoagulants; Atrial Appendage; Echocardiography, Three-Dimensional; Echocardiography, Transesophageal; Heart Diseases; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2013
Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood, 2003, Mar-01, Volume: 101, Issue:5 Topics: Adenoviridae; Aprotinin; Cells, Cultured; Collagen; Culture Media; Defective Viruses; Drug Synergism; Endothelial Growth Factors; Endothelium, Vascular; Fibrin; Fibroblast Growth Factor 2; Genetic Vectors; Heart Diseases; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinases, Membrane-Associated; Metalloendopeptidases; Neovascularization, Pathologic; Neovascularization, Physiologic; Phenylalanine; Protease Inhibitors; Thiophenes; Thrombosis; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-3; Transduction, Genetic; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
A replacement for warfarin: the search continues. Circulation, 2007, Jul-10, Volume: 116, Issue:2 Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin	2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thrombosis and haemostasis, 2007, Volume: 98, Issue:1 Topics: Adenosine Diphosphate; Adult; Aspirin; Biomarkers; Blood Cells; Calcium; Cells, Cultured; Female; Humans; Inflammation; Kinetics; Male; Middle Aged; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombosis; Up-Regulation	2007
Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. European journal of pharmacology, 2008, Jan-28, Volume: 579, Issue:1-3 Topics: Administration, Oral; Adult; Animals; Clopidogrel; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; In Vitro Techniques; Macaca fascicularis; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Thiophenes; Thrombosis; Ticlopidine	2008
S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood. Thrombosis research, 2008, Volume: 122, Issue:2 Topics: Animals; Biphenyl Compounds; Dose-Response Relationship, Drug; Humans; Indoleacetic Acids; Infusions, Intravenous; Inhibitory Concentration 50; Models, Chemical; Plasminogen Activator Inhibitor 1; Rats; Recombinant Proteins; Risk; Thiophenes; Thrombosis; Time Factors; Tissue Plasminogen Activator; Vitronectin	2008
For better or for worse: the future of antiplatelet therapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11 Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine	2008
[Status and trends in the field of inhibitors of thrombocyte function]. Folia haematologica (Leipzig, Germany : 1928), 1984, Volume: 111, Issue:4 Topics: Animals; Blood Platelets; Cyclic AMP; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation; Thiophenes; Thrombosis; Thromboxane-A Synthase; Ticlopidine	1984
Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs. Haemostasis, 1983, Volume: 13, Issue:1 Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Heparin; Lasers; Male; Mesenteric Arteries; Mesenteric Vascular Occlusion; Molsidomine; Oxazoles; Platelet Aggregation; Propionates; Pyrazoles; Pyrazolones; Rats; Rats, Inbred Strains; Sydnones; Thiophenes; Thrombosis; Ticlopidine	1983
The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs. Annals of the Royal College of Surgeons of England, 1984, Volume: 66, Issue:4 Topics: Arteries; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dipyridamole; Drug Therapy, Combination; Humans; Microscopy, Electron; Platelet Adhesiveness; Platelet Aggregation; Polyethylene Terephthalates; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine	1984
[Thrombus formation and its prevention during extracorporeal circulation--effect of preoperative administration with the antiplatelet drugs]. [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai, 1984, Volume: 32, Issue:12 Topics: Adult; Dipyridamole; Extracorporeal Circulation; Humans; Microscopy, Electron, Scanning; Platelet Adhesiveness; Platelet Aggregation; Platelet Count; Preoperative Care; Thiophenes; Thrombosis; Ticlopidine	1984
In vivo study of platelet aggregation in rats. Journal of pharmacological methods, 1984, Volume: 12, Issue:2 Topics: Adenosine Diphosphate; Animals; Aspirin; Collagen; Diet; Dose-Response Relationship, Drug; Male; Methods; Platelet Aggregation; Platelet Count; Rats; Rats, Inbred Strains; Thiophenes; Thrombosis; Ticlopidine	1984
Thrombotic etiology of stress ulcers. 1. The effect of anticoagulant and antiplatelet aggregators in the development of stress ulcers in rats. The American surgeon, 1983, Volume: 49, Issue:8 Topics: Animals; Anticoagulants; Aspirin; Dipyridamole; Gastric Acidity Determination; Gastric Mucosa; Heparin; Male; Peptic Ulcer Hemorrhage; Platelet Aggregation; Platelet Count; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Physiological; Thiophenes; Thrombosis; Ticlopidine	1983
Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications. Haemostasis, 1983, Volume: 13 Suppl 1 Topics: Animals; Anticoagulants; Blood Platelets; Hemodynamics; Humans; Kinetics; Thiophenes; Thrombosis; Ticlopidine	1983
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective. Arquivos brasileiros de cardiologia, 1983, Volume: 41, Issue:6 Topics: Anticoagulants; Bleeding Time; Humans; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine	1983
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective. Agents and actions, 1984, Volume: 14, Issue:1 Topics: Adenosine Diphosphate; Aspirin; Bleeding Time; Blood Platelets; Fibrinolytic Agents; Humans; Thiophenes; Thrombosis; Ticlopidine	1984
[Platelet aggregation inhibitors]. Revue de l'infirmiere, 1981, Volume: 31, Issue:19 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Dipyridamole; Humans; Platelet Aggregation; Pyridines; Thiophenes; Thrombosis; Ticlopidine	1981
A new in vivo model of arterial thrombosis: the effect of administration of ticlopidine and verapamil in dogs. Thrombosis research, 1982, Dec-01, Volume: 28, Issue:5 Topics: Administration, Oral; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Femoral Artery; Fibrinolytic Agents; Injections, Intravenous; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine; Verapamil	1982
Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study. Thrombosis research, 1980, Oct-15, Volume: 20, Issue:2 Topics: Adult; Aged; Blood Urea Nitrogen; Chlorides; Creatinine; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Kidney Failure, Chronic; Male; Middle Aged; Phosphoric Acids; Platelet Count; Pyridines; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine	1980
Effects of ticlopidine on thrombotic obstruction of A-V shunts and on dialysance of artificial kidneys. Artificial organs, 1980, Volume: 4, Issue:1 Topics: Adult; Arteriovenous Shunt, Surgical; Blood Coagulation; Female; Fibrinolytic Agents; Humans; Kidneys, Artificial; Middle Aged; Platelet Aggregation; Pyridines; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine	1980
Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 2. Sidechain optimization and demonstration of in vivo efficacy. Bioorganic & medicinal chemistry letters, 1999, Mar-08, Volume: 9, Issue:5 Topics: Animals; Anticoagulants; Binding Sites; Crystallography, X-Ray; Disease Models, Animal; Humans; Models, Molecular; Rats; Structure-Activity Relationship; Thiophenes; Thrombin; Thrombosis	1999
Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. Journal of medicinal chemistry, 1999, Sep-09, Volume: 42, Issue:18 Topics: Animals; Anticoagulants; Crystallography, X-Ray; Factor Xa Inhibitors; Humans; Models, Molecular; Molecular Structure; Pyrrolidinones; Rabbits; Rats; Serine Proteinase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Thiophenes; Thrombosis	1999
Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 5. Potency, efficacy, and pharmacokinetic properties of modified C-3 side chain derivatives. Journal of medicinal chemistry, 2000, Feb-24, Volume: 43, Issue:4 Topics: Animals; Anticoagulants; Binding Sites; Crystallography, X-Ray; Drug Evaluation, Preclinical; Humans; In Vitro Techniques; Models, Molecular; Pyrrolidines; Rats; Serine Proteinase Inhibitors; Structure-Activity Relationship; Thiophenes; Thrombin; Thrombosis	2000
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British journal of pharmacology, 2000, Volume: 129, Issue:7 Topics: Adenosine Diphosphate; Administration, Oral; Animals; Arteriovenous Shunt, Surgical; Binding, Competitive; Bleeding Time; Blood Platelets; Clopidogrel; Collagen; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Thionucleotides; Thiophenes; Thrombin; Thrombosis; Ticlopidine; Time Factors; Tritium	2000
17beta-estradiol, but not raloxifene, decreases thrombomodulin in the antithrombotic protein C pathway. Endocrinology, 2000, Volume: 141, Issue:10 Topics: Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Humans; Protein C; Pyrrolidines; Raloxifene Hydrochloride; Thiophenes; Thrombomodulin; Thrombosis; Umbilical Veins	2000
The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 301, Issue:1 Topics: Acrylates; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Blotting, Western; Body Weight; Dietary Fats; Disease Progression; Extracellular Matrix; Fibrinolysin; Gene Expression Regulation; Heart Rate; Hypertension; Imidazoles; Kidney Diseases; Male; Organ Size; Plasminogen Activator Inhibitor 1; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Serine Proteinase Inhibitors; Sodium Chloride, Dietary; Stroke; Thiophenes; Thrombosis	2002
Increase of platelet prostaglandin cyclic endoperoxides in thrombosis. Lancet (London, England), 1977, Jan-08, Volume: 1, Issue:8002 Topics: Blood Platelets; Clofibrate; Collagen; Dipyridamole; Heparin; Humans; Peroxides; Prospective Studies; Prostaglandins; Prostaglandins F; Pyridines; Sulfinpyrazone; Thiophenes; Thrombophlebitis; Thrombosis	1977
[Use of a new platelet aggregation inhibitor, ticlopidine, in hemodialysis]. Archivio "E. Maragliano" di patologia e clinica, 1979, Volume: 35, Issue:2 Topics: Adult; Aged; Blood Coagulation Disorders; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Aggregation; Pyridines; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine	1979
Anti-thrombotic action of ticlopidine, a new platelet aggregation inhibitor. Thrombosis research, 1978, Volume: 12, Issue:6 Topics: Acute Disease; Aminopropionitrile; Animals; Blood Coagulation; Collagen; Lactates; Lung Diseases; Male; Platelet Aggregation; Pyridines; Rats; Thiophenes; Thrombocytopenia; Thrombosis	1978
RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. Thrombosis research, 1988, Sep-01, Volume: 51, Issue:5 Topics: Animals; Arachidonic Acids; Blood Platelets; Dogs; Female; Humans; In Vitro Techniques; Male; Microsomes; Platelet Count; Prostaglandins; Rabbits; Rats; Rats, Inbred Strains; Thiophenes; Thrombosis; Thromboxane B2; Thromboxane-A Synthase	1988
Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. Thrombosis and haemostasis, 1986, Jun-30, Volume: 55, Issue:3 Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Line; Female; Humans; In Vitro Techniques; Male; Middle Aged; Neuroblastoma; Perfusion; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine	1986
[Prevention and medical treatment of polyregional vascular lesions]. Cardiologia (Rome, Italy), 1985, Volume: 30, Issue:11 Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Diet; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Risk; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine	1985
Antiplatelet aggregators inhibit development of stress ulcers in Sprague-Dawley rats. European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 1985, Volume: 17, Issue:1 Topics: Animals; Anticoagulants; Aspirin; Capillaries; Dipyridamole; Gastric Mucosa; Male; Platelet Aggregation; Pyridines; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Physiological; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine	1985
Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival. Thrombosis research, 1985, Jan-01, Volume: 37, Issue:1 Topics: Animals; Anticoagulants; Blood Platelets; Cell Survival; In Vitro Techniques; Male; Neuraminidase; Platelet Adhesiveness; Platelet Aggregation; Rabbits; Rats; Rats, Inbred Strains; Thiophenes; Thrombosis; Ticlopidine	1985
[Antithrombogenic therapy based on the study of the changes in platelet aggregability and blood coagulability in the early period after prosthetic valve replacement]. [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai, 1985, Volume: 33, Issue:1 Topics: Adult; Anticoagulants; Blood Coagulation; Dipyridamole; Female; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Male; Middle Aged; Platelet Aggregation; Postoperative Complications; Thiophenes; Thrombosis; Ticlopidine; Warfarin	1985
[Prevention of thrombosis of a blood vessel prosthesis using the anti-aggregation drug ticlid]. Kardiologiia, 1985, Volume: 25, Issue:8 Topics: Blood Vessel Prosthesis; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine	1985
Assessment of antithrombotic agents: effects of dipyridamole analogues on platelet behaviour. Cardiovascular research, 1972, Volume: 6, Issue:6 Topics: Adenosine Diphosphate; Animals; Blood Coagulation; Blood Platelets; Cerebral Arteries; Dipyridamole; Electrophoresis; Ethylamines; Morpholines; Norepinephrine; Piperazines; Platelet Adhesiveness; Pyrimidines; Rabbits; Structure-Activity Relationship; Thiophenes; Thrombosis	1972